ZHEJIANG ANGLIKANG PHARMACEUTICAL CO.,LTD.

Other languages Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
16.98 ^CNY	-0.88%		-5.09%	-21.79%

Apr. 26	Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Zhejiang AngLiKang Pharmaceutical CO.,LTD.'s Equity Buyback Plan announced on August 31, 2023.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25
Anglikang Pharmaceutical Signs Licensing Deal for Affinity Biomedical's Tumor Drug	Feb. 06
Anglikang Pharma's Unit Gets Nod for Enalapril Maleate Tablets	Jan. 29
Zhejiang AngLiKang Pharmaceutical CO.,LTD. announces an Equity Buyback for CNY 60 million worth of its shares.	23-08-30
Zhejiang AngLiKang Pharmaceutical CO.,LTD. authorizes a Buyback Plan.	23-08-29
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24
Anglikang Pharmaceutical's Unit Gets Veterinary, GMP Certificates	23-08-17
Anglikang Pharmaceutical Registers Metabolism Disorder Drug in China	23-06-27
Anglikang Pharma Obtains Nod to Market Sevoflurane Active Pharma Ingredient in China	23-06-16
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on May 19, 2023	23-05-12
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Approves Final Cash Dividend for 2022	23-04-24
Anglikang Pharma Signs Five-Year Purchase Agreement With European Firm	23-04-06
Zhejiang Anglikang Pharmaceutical Co.,Ltd. Proposes Final Cash Dividend for 2022	23-04-02
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30
Anglikang Pharma’s Drug to Lower Hypertension Fails to Make It on China’s Drug Procurement List	23-03-30
Chinese Shares End Mixed; Anglikang Pharma Slides 8% on 191 Million Yuan M&A Plan	23-03-24
Zhejiang Anglikang Pharma to Boost Stake in Local Biopharma Firm to 62% For 191 Million Yuan	23-03-24
Zhejiang AngLiKang Pharmaceutical CO.,LTD. completed the acquisition of an additional 38.22% stake in Hunan Kerey Pharmaceutical Co., Ltd. from Gan Hongxing, Hu Aiguo, Yang Xiangxin and Xie Laibin.	23-03-21
Zhejiang AngLiKang Pharmaceutical CO.,LTD. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Zhejiang AngLiKang Pharmaceutical CO.,LTD.

Equities

002940

CNE100003GC2

Other languages

Filters